Clinical Trials Browser

Phase 1 × Not yet recruiting × Myeloproliferative Disorders × Clear all

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT07379125 2026-01-30

Therapeutic RSK1 Targeting in Myelofibrosis

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Splenomegaly, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT07249840 2025-11-25

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

Phase 1 Not yet recruiting

12 enrolled

Myeloid

Myeloproliferative Disorders

NCT07020533 2025-06-13

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Phase 1 Not yet recruiting

46 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Clinical Trials

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Therapeutic RSK1 Targeting in Myelofibrosis

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant